ew diagnostic techniques in liver cancer
Not Applicable
- Conditions
- hepatocellular carcinoma (HCC)Cancer - Liver
- Registration Number
- ACTRN12613000194763
- Lead Sponsor
- Department of Nuclear Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Newly diagnosed HCC
Barcelona-Clinic Liver Cancer Stage O, A or B
Considered for transarterial chemoembolisation, radiofrequency ablation or resection
Exclusion Criteria
Pregnancy
Previously diagnosed benign or malignant lesions of the liver including HCC
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1: sensitivity and specificity of combined FCH and FDG PET scans for diagnosing HCC[At the time of diagnosis]
- Secondary Outcome Measures
Name Time Method 1: accuracy of predicting degree of differentiation and presence of microvascular invasion in newly diagnosed HCC using combined FDG and FCH PET scans[At time of diagnosis];2: accuracy of predicting time to progression and overall survival in newly diagnosed HCC using combined FDG and FCH PET scans[Death];3: accuracy of predicting treatment response, disease progression and disease recurrence after transarterial chemoembolisation for newly diagnosed HCC using combined FDG and FCH PET scans[6 weeks after transarterial chemoembolisation]